About Contact Us Careers

Coronary Artery Bypass Graft Devices Market Size & Share, by Product (Cardiopulmonary Bypass Equipment, Endoscopic Vessel Harvesting Systems, Cardiac Stabilizers, Graft Delivery Systems, Anastomosis Assist Devices); End user; Procedure; Source of Graft - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

  • Report ID: 8154
  • Published Date: Oct 01, 2025
  • Report Format: PDF, PPT

Coronary Artery Bypass Graft Devices Market Outlook:

Coronary Artery Bypass Graft Devices Market size was over USD 13.5 billion in 2025 and is estimated to reach USD 26.3 billion by the end of 2035, expanding at a CAGR of 7.7% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of coronary artery bypass graft devices is evaluated at USD 14.5 billion.

The increasing incidence of coronary artery disorders (CADs) is the primary propeller of the consumer base in the market. Testifying to the same, a report from the World Health Organization (WHO) unveiled that approximately 19.8 million worldwide died due to cardiovascular diseases (CVDs) in 2022, and 85% of these cases were caused by heart attack and stroke. Another NLM study underscored that CAD accounted for the highest age-standardized disability-adjusted life-years (DALYs), 2,275.9 per 100,000, around the globe out of all CVD types from 1990 to 2022. These figures indicate the substantial nature of demand in this sector.

Reimbursement policies and cost-containment strategies of payers are some of the pivotal contributors to shaping the pricing dynamics of the coronary artery bypass graft devices sector. As these financial backing service providers prioritize value-based models, the sector is gaining traction on account of the economic advantages of this treatment method. Testifying to the same, in 2022, the American Heart Association (AHA) published a comparative analysis on the cost-effectiveness of coronary artery bypass grafting (CABG) vs medical therapy (MED) in treating ischemic cardiomyopathy. It found out that CABG had a higher incremental cost-effectiveness ratio (ICER) of USD 63,989 for each quality-adjusted life-year (QALY), in comparison to MED.

Coronary Artery Bypass Graft Devices Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing population of high-risk individuals: Underlying conditions, such as diabetes and hypertension, contribute to the severity of CAD, leading to an increased demand for advanced surgical treatments, including CABG. As the global rise in these chronic ailments results in higher procedural volume, the consumer base of the coronary artery bypass graft devices industry continues to expand. Evidencing the same, a 2025 NLM study found that diabetes mellitus (DM) increases the severity of CAD, with higher rates of multi-vessel disease (68.6% vs. 50.9%), three-vessel disease (36.2% vs. 24.5%), and severe stenosis (62.7% vs. 50.9%), in comparison to non-diabetics.
  • Emergence of less invasive and robotic surgeries: The growing trend of choosing minimally invasive and robot-assisted surgeries over traditional open surgery is heightening the adoption rates in the market. The lower levels of post-operative complications, hospital stays, and recovery times are fueling traction in surgical robot utilization in this sector. Thus, the necessity of specialized, sophisticated devices to conduct these procedures is fostering a greater demand in this field. This surge can also be exemplified by the completion of 2,000 surgeries with the SSi Mantra Surgical Robotic System in September 2024, as per the press release from SS Innovations International.
  • Advances and innovations in devices’ efficacy: Introduction of cutting-edge graft materials, next-generation surgical technologies, and multi-specialty tools reflect continuous advancement of the market. These innovations notably enhanced the safety, efficacy, and recovery times associated with CABG procedures, making them more attractive to both surgeons and patients. Enhanced device precision and patient outcomes further encourage higher procedure volumes, boosting the surge in the sector. Currently, the integration of smart monitoring and imaging tools is supporting the pipeline to deliver better procedural success.

Historic Patient Pool Trends in the Coronary Artery Bypass Graft Devices Market

National Occurrence Rates of Ischemic Heart Disease (IHD)

(2017)

Region

Prevalence

(rate per 100,000)

Disability-Adjusted Life Years (rate per 100,000)

Germany

3,432

2,855

France

2,696

1,237

Italy

3,468

1,831

Spain

2,733

1,503

Netherlands

3,502

1,451

Switzerland

2,581

1,461

Sweden

3,858

2,192

Turkey

2,418

1,960

Russia

4,198

6,568

UK

3,337

1,864

China

1,612

2,131

India

1,197

2,679

Japan

2,928

1,427

South Korea

1,352

704

Taiwan

1,759

1,241

Saudi Arabia

1,509

1,643

Iran

1,599

2,149

Australia

2,576

1,450

U.S.

2,929

2,470

Canada

2,335

1,837

Brazil

1,685

1,736

South Africa

1,227

1,184
Source: NLM

Recent/Ongoing Development Cohorts in the Market

Study/Trial Name

Motive

Current Status

Year

No-Touch Vein Grafts in CABG

Examine if no-touch saphenous vein harvesting improves graft patency and outcomes

Completed, primary endpoint negative; increased leg wound complications

2025

ROMA Trial (Multiple vs Single Arterial Grafts)

Compare outcomes of single vs multiple arterial grafts in CABG patients

Ongoing or recently completed

2024

Thiamine in CABG (NCT06326996)

Assess if low-cost thiamine improves post-CABG outcomes

Recruiting/Active

2024

Preoperative Flow Assessment Before CABG (RCT)

Determine if pre-operative flow metrics improve surgical results in CABG

Study ongoing, mixed results

2025

Elana Device for Multi-Artery Heart Bypass (NCT07005843)

Evaluate the feasibility and safety of the Elana Anastomotic System for multi-artery anastomosis in CABG

Recruiting

2025
Source: NLM, AHA, and Clinicaltrials.gov

Challenges

  • Stringent pricing and reimbursement policies: In many markets, public payers set fixed coverage rates for entire procedure bundles, severely limiting the scope for premium-priced products in the coronary artery bypass graft devices market. Besides, these insurers demand additional real-world evidence for clinical and economic outcomes, extending the budget for research while shrinking profit margins. Moreover, the limitations in designing a product that delivers both high-end functions and potential to justify the extra cost within the fixed diagnosis-related groups (DRG) payment impose a notable adoption barrier in this sector, particularly for hospitals.
  • Pressures from alternative therapies: The expansion of the market is often pressurized by the increasing advancement and preference for percutaneous coronary interventions (PCIs). Such evolving treatment trends ultimately hinder consistency in revenue generation from this sector. To combat this problem, manufacturers are forced to compete for a share of a confined procedural volume that is not substantial in all geographies, intensifying the economic barriers for patients and budget-constrained medical settings.

Coronary Artery Bypass Graft Devices Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

7.7%

Base Year Market Size (2025)

USD 13.5 billion

Forecast Year Market Size (2035)

USD 26.3 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Coronary Artery Bypass Graft Devices Market Segmentation:

Product Segment Analysis

Cardiopulmonary bypass equipment is predicted to register the highest share of 28.9% in the coronary artery bypass graft devices market over the assessed period. The leadership is primarily attributed to its absolute necessity in the majority of on-pump CABG procedures. Complex multi-vessel grafts often require the hemodynamic stability and motionless field provided by cardiopulmonary bypass machines, which solidifies the segment’s position in this sector. Besides, ongoing advances are also propelling adoption in this segment, which can be exemplified by the FDA 510(k) Clearance for the Essenz Heart-Lung Machine by LivaNova for cardiopulmonary bypass procedures in March 2023. This broadened the pathway of the product’s commercial release in the U.S. marketplace.

End user Segment Analysis

Hospitals are estimated to dominate the coronary artery bypass graft devices market with a 75.4% share by the end of 2035. These facilities earned worldwide recognition as the primary end-user on account of their capacity in conducting high-complexity CABG procedures. Besides, the availability of public subsidies and post-operative management also makes them the first choice and point of care for a majority of cardiac surgeries. Moreover, the essential resources, such as integrated teams of surgeons, anesthesiologists, perfusionists, and specialized cardiac ICU nursing, are typically consolidated within major hospital settings, reinforcing their foundational role in this sector.

Procedure Segment Analysis  

he on-pump CABG is expected to remain the leading procedure in the coronary artery bypass graft devices market throughout the discussed timeframe, while acquiring 55.7% of the total share. This technique involves heavy use of a heart-lung machine to temporarily take over the heart’s function during a complex surgery and is widely preferred due to its established track record of effectiveness. This method enables better precision and better control, making it the gold standard for professionals in treating patients with multiple or severe blockages. Further, despite the rise of off-pump and minimally invasive alternatives, the reliability and widespread clinical acceptance maintain a strong presence of the segment in this field.

Our in-depth analysis of the market includes the following segments:

Segment

Subsegment

Product
  • Cardiopulmonary Bypass Equipment
  • Endoscopic Vessel Harvesting Systems
  • Cardiac Stabilizers
  • Graft Delivery Systems
  • Anastomosis Assist Devices

Procedure
  • On-Pump CABG
  • Anastomosis Assist Devices
  • Cannulae
  • Cardioplegia Delivery Systems
  • Endoscopic Vessel Harvesting Systems
  • Shunts and Clamps
  • Cardiopulmonary Bypass Machines
  • Off-Pump CABG
  • Stabilizers
  • Positioners
  • Anastomosis Assist Devices
  • Endoscopic Vessel Harvesting Systems
  • Heart Positioning and Compression Devices

End user
  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers

Source of Graft
  • Saphenous Vein Grafts
  • Internal Thoracic Artery Grafts
  • Radial Artery Grafts
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Coronary Artery Bypass Graft Devices Market - Regional Analysis

North America Market Insights

North America is poised to hold the largest share of 40.4% in the global coronary artery bypass graft devices market during the analyzed tenure. The increasing severity of CHD and CAD among high-risk populations and advanced medical systems collectively foster a lucrative business environment for the merchandise in this region. The wide acceptance of next-generation technologies, including minimally invasive and robot-assisted procedures, also ensures greater adoption in this field. In addition, strong government support, expanded reimbursement coverage, and robust investments in cardiac care facilities fuel growth in this landscape.

The presence of globally leading medical device manufacturers and research institutions in the U.S. solidifies its position in the North America market. Besides, the dominance of CABG in both procedural volumes and expenditure in the country also reflects the nation’s suitable environment for greater revenue generation in this category. As evidence, a 2024 NLM article unveiled that the total spending on CABG procedures was higher, accounting for approximately USD 16 billion, than PCIs, with an estimated total expenditure of USD 12 billion.

Canada is also one of the prominent contributors to the North America coronary artery bypass graft devices market. The country’s augmentation in this sector is primarily supported by its publicly funded healthcare system that ensures broad access to cardiac surgical procedures. Additionally, the substantial aging population and growing government focus on elderly care are fueling demand in this category. Thus, based on such an enlarging consumer base, hospitals in Canada are progressively adopting advanced CABG devices and minimally invasive techniques to improve patient outcomes and reduce recovery times.

Overview of Country-wise Procedural Volumes

Country

Procedural Volume

Timeline

U.S.

400,000 CABG procedures are performed annually, representing more than 70% of all cardiac surgery cases

2022-2024

Canada

Over 1,900 open-heart procedures are performed annually by the University of Ottawa Heart Institute alone

2025

Source: NLM and University of Ottawa Heart Institute

APAC Market Insights

Asia Pacific is expected to emerge as the fastest-growing region in the global coronary artery bypass graft devices market by the end of 2035. The rapidly increasing mortality rates of cardiovascular diseases (CVDs) due to urbanization, lifestyle-related disorders, and aging populations are cultivating a sustainable demand base in this landscape. Particularly, in emerging economies such as China and India, these factors are observed predominantly, where the age-standardized cardiovascular mortality rate (ASMR) is expected to be the highest in Central Asia, accounting for 676 deaths per 100,000 people by 2050, as reported by the NLM study.

The growing awareness about heart health and early diagnosis is increasing the demand in the China market. The country’s growing focus on adopting innovative surgical technologies and minimally invasive CABG assets is further propelling its growth at a remarkable pace. On the other hand, the strong emphasis of China on medical device technology development and production, along with alliance formation with global device manufacturers, further accelerates the expansion of the landscape.

Rigorous efforts to improve healthcare infrastructure in India, coupled with the rising disposable incomes and expanding health insurance coverage, are strengthening the country’s foundation in the coronary artery bypass graft devices market. Both government and private organizations are participating in this cohort of development, attracting a massive capital influx in this sector. Evidencing the same, in October 2023, SS Innovations launched a revolutionary robotic cardiac surgery program in India by utilizing its flagship SSi Mantra surgical robotic system, where more than 20 surgeries were already performed successfully in the country.

Europe Market Insights

Europe is estimated to continue being the second-largest shareholder in the global market over the timeline between 2026 and 2035. The presence of a well-established healthcare system, aging populations, and strong reimbursement policies is cumulatively establishing an attractive landscape for both domestic and foreign companies in this sector. Evidencing such expansion in the potential demography, a report from MedTech Europe estimated more than 155 million people living across the region to be aged over 65 by 2040.

With strong medical financial backing from the National Health Service (NHS), the UK is augmenting the coronary artery bypass graft devices market notably. In addition, the country has a well-established cohort of early screening and prevention programs, amplifying procedural volumes while improving surgical outcomes. This encourages more local and international pioneers to invest in this sector by enabling a greater scope of innovation and future expansion for the merchandise.

The expanding geriatric demography and growing demand for minimally invasive and off-pump procedures are amplifying the utilization rates in the Germany market. Additionally, favorable reimbursement policies and continuous investment in medical research further bolster the country’s growth in the regional landscape. Moreover, the strong emphasis of Germany on widespread cardiac care centers and the adoption of innovative surgical technologies are consolidating its proprietary position in Europe.

Country-wise Density of CABG Performed (2018-2023)

Country

Count of CABG Performed in 2018 (per 100,000)

Count of CABG Performed in 2023 (per 100,000)

Ireland

19.3

33.1

Cyprus

41.0

68.8

Luxembourg

15.6

20.2

Romania

20.8

23.8

Turkey

50.6

55.1

Source: Eurostat

Coronary Artery Bypass Graft Devices Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Coronary Artery Bypass Graft Devices Market Players:

    The commercial dynamics of the market feature the consolidated presence of global and regional MedTech pioneers who are focused on innovation, product development, and strategic partnerships. These innovators are primarily empowered by their extensive product portfolios and strong distribution networks. The competitive landscape in this sector is further structured by the ongoing emergence of less invasive surgical methods and robot-assistance, which are complemented by the continuous development of novel graft materials and devices.

    Such key players are:

    Company Name

    Country of Origin

    Global Share

    (2025)

    Industry Focus & Notable Products

    Medtronic plc

    Ireland

    ~22.4%

    cardiopulmonary bypass systems, endoscopic vessel harvesting (EVH) systems, cannulae, connectors, shunts, and tissue stabilizers

    Abbott Laboratories

    U.S.

    ~11.5%

    Anastomosis assist devices, vessel closure systems, and coronary guidewires

    Boston Scientific Corporation

    U.S.

    ~7.3%

    Embolic protection devices, guidewires, and imaging systems used in hybrid procedures

    LivaNova PLC

    UK

    ~6.6%

    Heart-lung machines (S5/S7), oxygenators, and perfusion systems for cardiopulmonary bypass

    Getinge AB

    Sweden

    ~5.3%

    Complete cardiopulmonary bypass solutions and advanced perfusion equipment

    Johnson & Johnson (Ethicon)

    U.S.

    ~xx%

    Surgical staplers, energy devices (e.g., Harmonic), and sutures for vessel harvesting and anastomosis

    Edwards Lifesciences Corp.

    U.S.

    ~xx%

    Critical care monitoring, vessel preparation, and cannulation products

    Teleflex Incorporated

    U.S.

    ~xx%

    Specialized vascular access cannulae, guidewires, and percutaneous surgical devices

    Becton, Dickinson and Co.

    U.S.

    ~xx%

    Surgical instrumentation and vessel harvesting tools

    B. Braun SE

    Germany

    ~xx%

    Surgical meshes for sternal closure, sutures, and surgical consumables

    Cardinal Health

    U.S.

    ~xx%

    Manufacturer and distributor of sterile surgical packs and disposable products

    Haemonetics Corporation

    U.S.

    ~xx%

    Blood management systems, including cell savers and autotransfusion devices

    CryoLife, Inc.

    U.S.

    ~xx%

    Biological surgical adhesives, sealants (BioGlue), and vascular grafts

    Euroflex

    Germany

    ~xx%

    Precision surgical instruments for cardiac surgery (forceps, scissors, stabilizers)

    Genesee Biomedical, Inc.

    U.S.

    ~xx%

    Specialized cardiovascular surgical instruments (clamps, needle holders, probes)

    Microline Surgical

    U.S.

    ~xx%

    Laparoscopic and endoscopic surgical systems for minimally invasive harvesting

    Vitalcor, Inc.

    U.S.

    ~xx%

    Disposable products for bypass and cardiac surgery (cannulae, connectors)

    AngioDynamics

    U.S.

    ~xx%

    Thrombectomy and thrombolytic devices with applications in vascular access

    Sorin Group (LivaNova)

    Italy

    ~xx%

    (Subsumed into LivaNova) Historical developer of cardiopulmonary equipment

    AMT Medical BV

    Netherlands

    ~xx%

    Developing minimal invasive medical devices for heart bypass surgery

    SS Innovations International, Inc.

    India

    ~xx%

    Leading the way in making surgical robotics more accessible

    Terumo Corporation

    Japan

    ~xx%

    Cardiopulmonary bypass circuits, oxygenators, arterial cannulae, and blood management systems

    Olympus Corporation

    Japan

    ~xx%

    Key products include endoscopic vessel harvesting (EVH) systems used to harvest saphenous veins for bypass grafts

    Below are the areas covered for each company in the market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In April 2025, AMT Medical raised a Series B funding of USD 25 million to accelerate the development of its revolutionary ELANA Heart Bypass System. This sutureless technology for coronary bypass surgery eliminates the need for open-heart surgery and opens the door to minimally invasive and even robot-assisted procedures.
  • In January 2024, SS Innovations signed a partnership with Medikabazaar to facilitate sales of its flagship SSi Mantra Surgical Robotic System to hospitals and medical facilities across India. The advanced, affordable, and accessible product offers multi-specialty usage with improved safety and efficiency.
  • Report ID: 8154
  • Published Date: Oct 01, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of the coronary artery bypass graft devices market was over USD 13.5 billion.

The market size for the coronary artery bypass graft devices market is projected to reach USD 26.3 billion by the end of 2035, expanding at a CAGR of 7.7% during the forecast period, i.e., between 2026-2035.

The major players in the market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Getinge AB, Johnson & Johnson (Ethicon), and others.

In terms of product, the cardiopulmonary bypass equipment segment is anticipated to garner the largest market share of 28.9% by 2035 and display lucrative growth opportunities during 2026-2035.

The market in North America is projected to hold the largest market share of 40.4% by the end of 2035 and provide more business opportunities in the future.

Coronary Artery Bypass Graft Devices Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos